{"id":"marevan","safety":{"commonSideEffects":[{"rate":"2-4","effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Bruising"},{"rate":"0.1-0.5","effect":"Skin necrosis"},{"rate":"0.1","effect":"Warfarin-induced thrombosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Marevan (warfarin) works by blocking the enzyme vitamin K epoxide reductase, which is essential for the recycling of vitamin K. This prevents the gamma-carboxylation of clotting factors II, VII, IX, and X, reducing their activity and prolonging the prothrombin time (PT/INR). The anticoagulant effect develops over several days as existing clotting factors are cleared from circulation.","oneSentence":"Marevan is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors, thereby reducing blood coagulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:01.754Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Post-myocardial infarction thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT02740712","phase":"PHASE1","title":"Pharmacokinetic Drug-Drug Interaction Study of Rucaparib","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2016-04","conditions":"Neoplasms","enrollment":17},{"nctId":"NCT04235569","phase":"PHASE4","title":"Warfarin Initiation in Mechanical Mitral Valve Replacement Patients","status":"COMPLETED","sponsor":"Sarah Sabry Hashem","startDate":"2018-03-01","conditions":"Mitral Valve Disease","enrollment":50},{"nctId":"NCT02017197","phase":"PHASE4","title":"Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2014-08","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT00700895","phase":"PHASE3","title":"Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2006-08","conditions":"Indications for Warfarin Therapy","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["warfarin"],"phase":"marketed","status":"active","brandName":"Marevan®","genericName":"Marevan®","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Marevan® (warfarin) inhibits vitamin K-dependent clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}